Irfan Ahsan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Irfan Ahsan has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Bilal Haider Lashari
Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, PA, United States
1 shared publication - Ida Micaily
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia, United States of America
1 shared publication Joseph Crocetti
Pulmonary and Critical Care, Abington Hospital-Jefferson Health, Abington, PA, USA
1 shared publication- Mohsin Hamid
Abington Memorial Hospital, Abington, PA, USA
1 shared publication Usman Sarwar
Department of Internal Medicine, Abington Hospital-Jefferson Health, Abington, PA, USA
1 shared publication
Latest Publications
- Open Access
- 4 May 2018
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 8 (3) , 149-151
A deadly prescription: combination of methotrexate and trimethoprim-sulfamethoxazole
Methotrexate (MTX) is a chemotherapeutic synthetic(s) phase cell cycle inhibitor, and its role has evolved as an immunological agent in autoimmune diseases like rheumatoid arthritis, psoriasis, and systemic lupus erythematosus, etc. Trimethoprim-sulfamethoxazole (TS) is one of the most widely prescribed antibiotics commonly used for urinary tract infections, exacerbations of chronic bronchitis, traveler's diarrhea, and pneumocystis pneumonia. Both MTX and TS can have significantly overlapping side effects involving dermatologic, renal, and hematological systems, and the combination of these can be deadly. Our case is about the combination of MTX and TS that leads to mucocutaneous ulceration, leukopenia, and renal insufficiency. The purpose of this case is to increase awareness of potentially significant toxicity from the combination of MTX with TS. Abbreviations: MTX: methotrexate; TS: trimethoprim-sulfamethoxazole; ED: emergency department; IV: intravenous; GI: gastrointestinal; NSAIDs: nonsteroidal anti-inflammatory drugs.
- 4 May 2018
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 8 (3) , 149-151
Open AccessA deadly prescription: combination of methotrexate and trimethoprim-sulfamethoxazole
Methotrexate (MTX) is a chemotherapeutic synthetic(s) phase cell cycle inhibitor, and its role has evolved as an immunological agent in autoimmune diseases like rheumatoid arthritis, psoriasis, and systemic lupus erythematosus, etc. Trimethoprim-sulfamethoxazole (TS) is one of the most widely prescribed antibiotics commonly used for urinary tract infections, exacerbations of chronic bronchitis, traveler's diarrhea, and pneumocystis pneumonia. Both MTX and TS can have significantly overlapping side effects involving dermatologic, renal, and hematological systems, and the combination of these can be deadly. Our case is about the combination of MTX and TS that leads to mucocutaneous ulceration, leukopenia, and renal insufficiency. The purpose of this case is to increase awareness of potentially significant toxicity from the combination of MTX with TS. Abbreviations: MTX: methotrexate; TS: trimethoprim-sulfamethoxazole; ED: emergency department; IV: intravenous; GI: gastrointestinal; NSAIDs: nonsteroidal anti-inflammatory drugs.